In the setting of increased ATP demand, XO-mediated ROS can decrease mitochondrial respiration and contractile function. Thus, we tested the hypothesis that XO inhibition improves cardiomyocyte bioenergetics and LV function in chronic ACF in the rat. Sprague-Dawley rats were randomized to either sham or ACF Ϯ allopurinol (100 mg·kg Ϫ1 ·day Ϫ1 , n Ն7 rats/group). Echocardiography at 8 wk demonstrated a similar 37% increase in LV end-diastolic dimension (P Ͻ 0.001), a twofold increase in LV end-diastolic pressure/wall stress (P Ͻ 0.05), and a twofold increase in lung weight (P Ͻ 0.05) in treated and untreated ACF groups versus the sham group. LV ejection fraction, velocity of circumferential shortening, maximal systolic elastance, and contractile efficiency were significantly depressed in ACF and significantly improved in ACF ϩ allopurinol rats, all of which occurred in the absence of changes in the maximum O 2 consumption rate measured in isolated cardiomyocytes using the extracellular flux analyzer. However, the improvement in contractile function is not paralleled by any attenuation in LV dilatation, LV end-diastolic pressure/wall stress, and lung weight. In conclusion, allopurinol improves LV contractile function and efficiency possibly by diminishing the known XO-mediated ROS effects on myofilament Ca 2ϩ sensitivity. However, LV remodeling and diastolic properties are not improved, which may explain the failure of XO inhibition to improve symptoms and hospitalizations in patients with severe heart failure. heart failure; volume overload; xanthine oxidase; mitochondria A PURE VOLUME OVERLOAD (VO), without an increase in systolic pressure, increases diastolic load and results in an adverse eccentric left ventricular (LV) hypertrophy and remodeling manifested by wall thinning, cardiomyocyte elongation, and a decrease in the LV mass to volume.Currently, there is no medical therapy to attenuate this remodeling process and progression to heart failure (10). Recently, our laboratory has demonstrated increased cardiomyocyte oxidative stress in patients with VO of isolated chronic mitral regurgitation (1) and in rats with VO of aortocaval fistula (ACF) (18, 39). Specifically, xanthine oxidase (XO) is elevated in cardiomyocytes along with myofibrillar degeneration and mitochondrial dysfunction and damage, despite a preserved LV ejection fraction (LVEF). The preservation of LV shortening has been shown to belie underlying cardiomyocyte dysfunction due to ejection into the low pressure left atrium and, in this animal model, ejection into the aortovenous fistula. XO is a critical mediator of ATP and purine degradation and produces ROS when O 2 is used as an electron acceptor during purine metabolism (30). We have postulated that increased myocardial O 2 demand in the volume-overloaded heart with increased XO activity and ATP turnover sets up a vicious cycle of ROS production that can negatively impact multiple processes in the cardiomyocyte by altering mitochondrial function and production of ROS that impact other sensiti...